Companies / IIQ

INOVIQ LTD

ASX:IIQHealth Care Equipment & Services
140.8M shares on issueASX (delayed) · as of 28 July 2026$0.20price · delayed$28.2Mmarket cap · indicative
C
Dilution grade

Runway 2–4 quarters; share count grew 28% in 24 months; 1 cash raise in 24 months

Cash runway3.4 quarters of funding
Share-count growth (24m)27.7%
Raise cadence (24m)1 cash raise
Options & rights overhang6.2% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

INOVIQ LTD's ordinary share count rose 27.7% between July 2024 and November 2025, to 141M shares. The company raised capital once in that period for total proceeds of A$10.2M, most recently in October 2025 when it recorded A$10.2M of proceeds. Options and rights on issue could convert into 9M new shares, equal to 6.2% of the current share count, with 0% reported as in the money. At the June 2026 quarter the company reported A$8.6M in available cash, equivalent to 3.4 quarters of funding at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
6.2%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
3.4 qtrs
Cash cover · 2–4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 140.8M per ASX (delayed) (28 July 2026).
117.7M126.2M134.6MDec 24Sept 25July 26Cash raise · 8 Oct 2025

Cash runway

3.4 qtrs
Two to four quarters of funding at the recent spend rate.
$8.6M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 June 20263H · cancellationIIQ : ORDINARY FULLY PAID140.8MAppendix 3H
16 Jan 20263G · unquotedIIQ : ORDINARY FULLY PAID140.8MAppendix 3G
18 Dec 20253H · cancellationIIQ : ORDINARY FULLY PAID140.8MAppendix 3H
3 Nov 20252A · quoted issueIIQ : ORDINARY FULLY PAID140.8MAppendix 2A
16 Oct 20252A · quoted issueIIQ : ORDINARY FULLY PAID138.8MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$10.2M
Capital raise
8 Oct 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

6.2%
Total overhang · of current shares
0.0%
In the money · at current price
8.8M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
8 July 2026Dr Geoffrey CummingOther———3Y notice
8 July 2026Max JohnstonOther———3Y notice
8 July 2026Philip PowellOther———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

15 July 2026Change of Director's Interest Notice
13 July 2026$PEXO-OC Study Outcome Investor Webinar Presentation
12 July 2026$PQuarterly Activities Report and Appendix 4C - June 2026
7 July 2026Investor Briefing on EXO-OC Test and study outcome
30 June 2026$PEXO-OC algorithm and clinical study update
28 June 2026$PTrading Halt
26 June 2026Notification of cessation of securities - IIQ
24 June 2026$PPositive CAR-exosome data in ovarian cancer
17 June 2026$PResponse to ASX Price Query
25 May 2026Change of Director's Interest Notice - Peter Gunzburg
21 May 2026Change of Director's Interest Notice - Peter Gunzburg
18 May 2026Change of Director's Interest Notice - Peter Gunzburg
27 Apr 2026$PQuarterly Activities Report and Appendix 4C - March 2026
1 Apr 2026Change of Director's Interest Notice - Max Johnston
29 Mar 2026Change of Director's Interest Notice - Mary Harney
12 Mar 2026Change of Director's Interest Notice - Peter Gunzburg
2 Mar 2026Change of Director's Interest Notice - Peter Gunzburg
22 Feb 2026Change of Director's Interest Notice - Peter Gunzburg
17 Feb 2026$PAppendix 4D and FY26 Half Year Financial Report
28 Jan 2026$PQuarterly Business Update and Appendix 4C - December 2025

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.